Rhythm Pharmaceuticals Launches IMCIVREE in Japan for Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc. (RYTM) announced the commercial launch of its drug IMCIVREE (setmelanotide) in Japan to treat patients with acquired hypothalamic obesity. The rollout follows the drug's inclusion on Japan's National Health Insurance price list, making IMCIVREE the first approved therapy in Japan for this rare neuroendocrine condition.
The commercial availability expands treatment options in a market where Rhythm Pharmaceuticals estimates between 5,000 and 8,000 individuals live with acquired hypothalamic obesity. Japan's Ministry of Health, Labour and Welfare previously granted the drug orphan status and approved it in August based on pivotal Phase 3 TRANSCEND trial data, which showed a statistically significant 18.8% placebo-adjusted reduction in body mass index.
Rhythm Pharmaceuticals has been expanding its Japanese operational team to support commercial distribution. Shares of the company traded at $86.61 following the announcement. Investors will monitor early adoption in Japan alongside the company's broader pipeline of treatments for rare neuroendocrine conditions.
Key points
- Rhythm Pharmaceuticals launched IMCIVREE in Japan for patients with acquired hypothalamic obesity following inclusion on the national price list.
- IMCIVREE represents the first approved therapy in Japan for acquired hypothalamic obesity.
- Japan's Ministry of Health, Labour and Welfare granted the drug orphan designation and approved it in August 2026.
- Phase 3 trial results showed an 18.8% placebo-adjusted reduction in body mass index among patients with acquired hypothalamic obesity.
- Rhythm Pharmaceuticals estimates that between 5,000 and 8,000 people in Japan live with the condition.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is IMCIVREE approved to treat in Japan?
IMCIVREE is approved in Japan to treat patients with acquired hypothalamic obesity, making it the first authorized therapy for this condition in the country.
How effective was IMCIVREE in clinical trials for acquired hypothalamic obesity?
In the pivotal Phase 3 TRANSCEND trial involving 142 patients, IMCIVREE demonstrated a statistically significant 18.8% placebo-adjusted reduction in body mass index.
How many people in Japan are affected by acquired hypothalamic obesity?
Rhythm Pharmaceuticals estimates that approximately 5,000 to 8,000 people in Japan live with acquired hypothalamic obesity.